Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Study of the Role of Circulating Tumor DNA in Predicting the Likelihood of Organ Preservation After Clinical Complete Response to Neoadjuvant Therapy for Rectal Cancer

NCT03749083 is registered in ClinicalTrials.gov with Massachusetts General Hospital as lead sponsor.

NCT NCT03749083
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03749083 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Study of the Role of Circulating Tumor DNA in Predicting the Likelihood of Organ Preservation After Clinical Complete Response to Neoadjuvant Therapy for Rectal Cancer
Lead sponsor
Massachusetts General Hospital
Phase
Observational
Overall status
Withdrawn
Start date
December 31, 2019
Completion date
October 31, 2024
Enrollment
0 (actual)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

gastrointestinal malignancies